Johnson & Johnson's Q2 Earnings: Revenue And Profit Beat On Strong Pharma Sales, Annual Profit Outlook Lowered On M&A Costs
Portfolio Pulse from Vandana Singh
Johnson & Johnson (NYSE: JNJ) reported strong Q2 earnings with a 10.2% increase in adjusted EPS and a 4.3% rise in sales, driven by strong pharma sales. However, the company lowered its annual profit outlook due to M&A costs.
July 17, 2024 | 12:14 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Johnson & Johnson reported a strong Q2 with a 10.2% increase in adjusted EPS and a 4.3% rise in sales, driven by strong pharma sales. However, the company lowered its annual profit outlook due to M&A costs.
While JNJ reported strong Q2 earnings and sales growth, the lowered annual profit outlook due to M&A costs may offset the positive sentiment. This mixed news is likely to result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100